University Hospital Schleswig-Holstein
Kiel, 24105, Germany
Location status: Recruiting
Location contact
Henning Wieker
PRINCIPAL_INVESTIGATOR
Martin Laudien
CONTACT
Valeria Rodau
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07311876
The objective of this study is to evaluate the Symani System's safety and effectiveness for microsurgical anastomosis during open lymphatic reconstruction in the head and neck.
Interested in participating?
Request Info22 year and older
All sexes
Interventional
Not applicable
Kiel, 24105, Germany
Location status: Recruiting
Henning Wieker
PRINCIPAL_INVESTIGATOR
Martin Laudien
CONTACT
Valeria Rodau
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Symani® Surgical System is intended to perform surgical techniques during open microsurgical procedures.
Time frame: The duration of the participants' index procedure.
Intraoperative anastomosis patency prior to closure will be measured for each robotic anastomosis using indocyanine green (ICG) fluorescence imaging and will be evaluated prior to closure of the procedure site during the index procedure.
Time frame: The duration of the participants' index procedure through 30 days.
All adverse events will be evaluated from the start of the index procedure through 30 days post index procedure.
Time frame: From the pre-operative visit through 6 months post index procedure.
Change in flow pathways will be assessed by an ICG lymphangiography
Time frame: From the pre-operative visit through 6 months post index procedure.
Scale ranges from 0-3, the higher score indicating worse disease state.
Time frame: From the pre-operative visit through 6 months post index procedure.
Time frame: From the pre-operative visit through 6 months post index procedure.
It contains 33 items (symptoms) which are answered Yes or No. If the response is Yes to any given item, the patient is asked to rate the intensity of the symptom on a 5-point Likert scale. Each symptom then receives a score ranging from 0 (does not experience the symptom) to 5 (experiences the symptom with severe intensity).
Time frame: From the pre-operative visit through 6 months post index procedure.
Assessed by Fiberoptic Endoscopic Evaluation of Swallowing (FEES) Examination
Time frame: The duration of the participants' index procedure.
as freedom from any device malfunction resulting in unplanned conventional (manual) suturing
Time frame: The duration of the participants' index procedure through 30 days post index proceudre.
Time frame: The duration of the participants' index procedure through 30 days post index proceudre.
Time frame: The duration of the participants' index procedure through 30 days post index proceudre.
Time frame: The duration of the participants' index procedure through 30 days post index proceudre.
Contact information is provided by the study sponsor or research team.
MMI (Medical Microinstruments, Inc.)
Industry
Acronym: CLEAR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04797390
Hemic and Lymphatic Diseases, Lymphatic Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT06912763
Fibrosis, Fibrosis Syndrome
Houston, Texas, United States
View Trial DetailsNCT07708662
Chronic Edema, Hemic and Lymphatic Diseases
Edegem, Antwerp, Belgium
View Trial DetailsNCT05142800
Breast Cancer, Breast Cancer Lymphedema
Boston, Massachusetts, United States
View Trial Details